October 2024 in “Canadian Journal of Health Technologies” Olumiant should be covered for severe alopecia areata if certain conditions are met.
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
22 citations
,
February 2000 in “Journal of the American Academy of Dermatology” Eosinophils are not a reliable marker for diagnosing alopecia areata.
January 2026 in “Annals of Dermatology” Alitretinoin may help treat mild to moderate alopecia areata.
May 2020 in “JAAD case reports” Using anthralin and calcipotriene together might help treat tough cases of alopecia areata, but more research is needed to understand how it works.
June 2025 in “British Journal of Dermatology” Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
6 citations
,
June 2021 in “EClinicalMedicine” ALRV5XR significantly improves hair density in women with hair loss and is well-tolerated.
September 2025 in “Journal of the American Academy of Dermatology” Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.
6 citations
,
October 2018 in “Drug safety - case reports” Alitretinoin may cause irreversible hair curling as a side effect.
December 2025 in “International Journal of Innovative Technologies in Social Science” Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
5 citations
,
May 1983 in “Australian journal of biological sciences” Certain amino acid analogues can inhibit wool and hair growth and affect fiber strength.
TrichoSolTM is safe for hair loss treatments with specific ingredient stability for up to 180 days.
26 citations
,
May 1991 in “Clinical and experimental dermatology” Oral etretinate improved hair length and reduced beading in monilethrix.
January 2021 in “Figshare” Tiny lipid particles carrying 17-α-estradiol gather in hair follicles, which may help target alopecia treatment.
June 2025 in “British Journal of Dermatology” Tofacitinib was more effective than methotrexate for treating alopecia areata.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
July 2024 in “Journal of Investigative Dermatology” ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.
February 2020 in “Zagazig University Medical Journal” The treatment is effective for mild alopecia areata but often causes mild side effects.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
May 2008 in “10th European Congress of Endocrinology” September 2025 in “Pharmaceutics” Quercetin nanocrystal gel shows promise for hair regrowth in androgenetic alopecia.
February 2026 in “Revista Eletrônica Polidisciplinar Voos.” A balanced approach using dutasteride and Serenoa repens can improve hair transplant success by protecting follicles and minimizing side effects.
April 2025 in “International Journal of Dermatology” JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.
1 citations
,
August 2022 in “Journal of Dermatological Treatment” Dutasteride is the most effective for hair loss but may cause sexual and mental side effects.
5 citations
,
July 2010 in “Archives of Internal Medicine” Prostaglandins may protect hair follicles during chemotherapy.
July 2025 in “Pakistan Journal of Intensive Care Medicine” Clobetasol propionate 0.05% ointment is more effective than tacrolimus 0.1% ointment for treating alopecia areata.
October 2021 in “Journal of Investigative Dermatology” Edelweiss extract may help prevent hair loss and increase hair density.
October 2015 in “Elsevier eBooks” Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.